Coloplast Shares Slip Amid Mixed Earnings Outlook
Coloplast A/S (ticker COLO‑B.CO) traded down 1.39 % during the 24‑hour period ending at 02:06 PM Central Europe on Thursday, 22 November 2026. At the close, one share was available for purchase at approximately DKK 472.70 on the OMX Nordic Exchange. The company’s total outstanding shares amount to 207.4 million, and its current market capitalisation stands at DKK 105.8 billion. In the last 24 hours, roughly DKK 135.5 million of Coloplast shares were exchanged.
Market Context
Since the close of the previous month, Coloplast’s share price has climbed 11.63 %, a rebound that has been tempered by the latest earnings release. The company’s simple moving average for the last 200 days sits at DKK 441.92, while its 52‑week high and low were DKK 631.40 (5 November 2025) and DKK 369.70 (18 June 2026), respectively. Current short interest remains moderate, positioning Coloplast among the lower‑tier Danish stocks in terms of short‑selling activity.
Earnings Release and Guidance
The modest decline in share price reflects a cautious market stance amid broader volatility. Coloplast’s earnings report for the fiscal year ending 2025‑26 was mixed: revenue and profit figures did not substantially exceed expectations, yet the company signaled a gradual shift toward a more stable outlook. Analysts noted that while the guidance is tempered, it suggests a potential turnaround in subsequent periods. A conference call scheduled for 3 November will provide further detail on the results and address analyst questions, offering investors a clearer view of the company’s trajectory.
Comparative Performance of Related Danish Stocks
| Stock | Ticker | 24‑Hour Move | Current Price (DKK) | Market Cap (DKK bn) | P/E Ratio |
|---|---|---|---|---|---|
| Demant A/ | DEMANT.CO | +0.5 % | 356.8 | 76.7 | 31.36 |
| Nkt A/ | NKT.CO | +0.97 % | 814 | 44.7 | 22.6 |
| Al Sydbank | ALSYDB.CO | 0 % | 690 | 59.6 | 20.9 |
| Alk‑abello A/ | ALK‑B.CO | +2.02 % | 241 | 53.7 | 39.72 |
| ISS A/ | ISS.CO | –0.14 % | 292.2 | 45.6 | 17.24 |
The table illustrates that while Coloplast experienced a slight dip, its peers largely maintained or improved their positions, reflecting sector‑wide resilience amid earnings season.
Strategic Highlights
Coloplast’s portfolio remains anchored in three core segments:
- Chronic Care – devices and supplies for long‑term conditions.
- Interventional Urology – minimally invasive surgical products.
- Wound & Skin Care – advanced dressings and related services.
The company’s global reach, headquartered in Humlebaek, Denmark, underscores its commitment to innovation in intimate healthcare products. More detailed information on Coloplast’s operations is available on its website, www.coloplast.com , and the company continues to trade on the OMX Nordic Exchange Copenhagen AS.
Outlook
Investors will likely monitor the upcoming conference call for insights into Coloplast’s strategic priorities, particularly any updates on product development pipelines and geographic expansion plans. While short interest remains modest, the company’s performance will continue to be influenced by broader sector dynamics and overall investor sentiment toward the long‑term healthcare equipment market.
